Breast cancer specialist named director of Vanderbilt-Ingram Cancer Center

February 26, 2022

1 minute read


We have not been able to process your request. Please try again later. If you continue to have this problem, please contact [email protected]

Ben Ho Park, MD, PhD, was named director of the Vanderbilt-Ingram Cancer Center.

Ben Ho Park, MD

Ben Ho Park

Park, who joined Vanderbilt in 2018 from Sidney Kimmel Comprehensive Cancer Center, has served as deputy director of the cancer center since 2021. He is also director of the division of hematology and oncology and director of precision oncology.

Park will begin his new role on July 1.

He will succeed Jeansnotifer Pietenpol, PhD, who was director of the cancer center for 15 years. As Healio reported earlier this month, Pietenpol will take over as scientific and strategic director of Vanderbilt University Medical Center this summer.

Jennifer Pietenpol, PhD

Jeansnotifer Pietenpol

“I am delighted that Dr. Park has accepted the position of director. He will lead the next phase in the trajectory of Vanderbilt-Ingram Cancer Center, and there is no doubt that the future is bright,” Pietenpol said in a press release. “Since joining Johns Hopkins in 2018, Ben has brought us new and innovative approaches to cancer care, including molecular tumor arrays that deliver precision oncology to our patients, both within and across the body. beyond our ever-expanding catchment area. He is a highly respected physician scientist, deeply committed to his patients, internationally recognized for his research, and a leader who catalyzes collaboration and excellence.

Park is known for his expertise in the field of breast cancer. His research team identified a high frequency of PIK3CA mutations in breast cancer. This discovery led to the development of phosphatidylinositol 3-kinase (PI3 kinase) inhibitors. He also helped pioneer the use of cell-free liquid DNA biopsies to guide therapy.

“I welcome Dr. Park to this important role on our leadership team. His decades of experience and remarkable accomplishments as a clinical and academic leader, including in the rapidly growing field of precision oncology, make him the ideal person to lead our cancer center into the future,” Jeff Balser, MD, PhD, president and CEO of Vanderbilt University Medical Center and dean of the Vanderbilt University School of Medicine, said in the statement.

Comments are closed.